InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,372.63
(
-0.81%
)
Post# of 251715
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 211164

Tuesday, 11/28/2017 9:24:30 AM

Tuesday, November 28, 2017 9:24:30 AM

Post# of 251715
PFE/Merck KGaA—Bavencio phase-3 fails in gastric cancer:

https://www.prnewswire.com/news-releases/merck-and-pfizer-provide-update-on-phase-iii-javelin-gastric-300-study-in-patients-with-pre-treated-advanced-gastric-cancer-660493023.html

This trial compared Bavencio monotherapy to standard chemotherapy in third-line gastric cancer irrespective of PD-L1 expression. The primary endpoint was OS.

Bavencio is approved for bladder cancer (#msg-131199162) and MCC (#msg-129810893). It is alos being tested in NSCLC (#msg-118239759).

Please see #msg-135830618 and #msg-108253419 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up